Navigation Links
SynCardia Total Artificial Heart Surpasses 100th Implant of 2013
Date:7/25/2013

Tucson, Ariz. (PRWEB) July 25, 2013

SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that as of July 18, a record-breaking 100 implants of the SynCardia temporary Total Artificial Heart have been performed by SynCardia Certified Centers in 2013. This milestone was achieved three months earlier than in 2012, when the 100th implant was performed on Oct. 16.

2012 was a record-breaking year for SynCardia with 125 implants of the Total Artificial Heart at 54 SynCardia Certified Centers,” said Michael Garippa, SynCardia CEO and President. “Reaching 100 implants three months earlier than we did last year is a testament to our long-term growth trajectory, which will be close to tripling since 2009. We expect this growth to continue as more hospitals adopt the Total Artificial Heart as the new standard of care for end-stage biventricular heart failure.”

The 100th implant of the Total Artificial Heart was performed by Virginia Commonwealth University (VCU) Medical Center in Richmond, one of the most experienced SynCardia Certified Centers in the world. The surgery marked VCU Medical Center’s 75th Total Artificial Heart implant since becoming a SynCardia Certified Center in 2006.

“From January 2012 through the first seven months of 2013, there have been 230 implants of the Total Artificial Heart,” said Garippa. “This is nearly double the number of implants performed during the same 19-month period from 2010 to 2011, in which 120 implants were performed.”

SynCardia is currently awaiting a response from the FDA regarding its premarket approval supplement for the Freedom® portable driver, the world’s first wearable power supply for the Total Artificial Heart. To date, 140 patients have been supported by the Freedom portable driver worldwide, accounting for more than 68 patient years of support. Of these patients, 89 were discharged from the hospital to wait for a matching donor heart at home and in their communities.

The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.

CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.

###

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 315 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among “America's Most Promising Companies”

In its February 2013 issue, Forbes selected SynCardia as one of “America's Most Promising Companies” for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

Read the full story at http://www.prweb.com/releases/2013/7/prweb10963589.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. SynCardia Total Artificial Heart Bridges Mother of Four with Congenital Heart Defect & Biventricular Heart Failure to Transplant
2. Medical Design Excellence Awards Selects Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart as Silver Winner
3. 7 SynCardia Certified Centers Honored Among “Best Children’s Hospitals” for Cardiology and Heart Surgery by U.S. News & World Report
4. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
5. SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre
6. Nebraska Medical Center Implants States First SynCardia Total Artificial Heart
7. University of Kentucky Medical Center Transplants States 1st SynCardia Total Artificial Heart Patient
8. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
9. 2012 American Business Awards?Honors SynCardia with Two Gold Stevie® Awards
10. Pressure BioSciences, Inc. Closes Final Tranche of Series J Above Market Private Placement - Total Amount Raised in PIPE Slightly Exceeds $2 Million Goal
11. GSMA: The Adoption Of mHealth Could Reduce Total Annual European Healthcare Spend By Almost Euro 100 Billion In 2017
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs ... to include an array of biochemical analyses critical for Lead Discovery. The ... hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, and ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Capitol Hill neighborhood, with its swanky shops, parks and cafés, might ... salon to set up shop. But there,s Hair Fairies ... on E Madison Ave, and CEO Maria Botham ... we pride ourselves on being a destination for parents and ... associated with lice. Everyone can get lice – it doesn,t ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 Report Highlights The global ... $8.3 billion in 2016 at a compound annual growth ... Report Includes - An overview of the global market ... data from 2015 and 2016, and projections of compound ... the market on the basis of product type, source, ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):